369 related articles for article (PubMed ID: 22806955)
1. Surgical management of rectal gastrointestinal stromal tumors.
Tielen R; Verhoef C; van Coevorden F; Reyners AK; van der Graaf WT; Bonenkamp JJ; van Etten B; de Wilt JH
J Surg Oncol; 2013 Mar; 107(4):320-3. PubMed ID: 22806955
[TBL] [Abstract][Full Text] [Related]
2. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
[TBL] [Abstract][Full Text] [Related]
4. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour.
Machlenkin S; Pinsk I; Tulchinsky H; Ziv Y; Sayfan J; Duek D; Rabau M; Walfisch S
Colorectal Dis; 2011 Oct; 13(10):1110-5. PubMed ID: 21040362
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
[TBL] [Abstract][Full Text] [Related]
6. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib.
Wilkinson MJ; Fitzgerald JE; Strauss DC; Hayes AJ; Thomas JM; Messiou C; Fisher C; Benson C; Tekkis PP; Judson I
Br J Surg; 2015 Jul; 102(8):965-71. PubMed ID: 25970743
[TBL] [Abstract][Full Text] [Related]
7. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study.
Colombo C; Ronellenfitsch U; Yuxin Z; Rutkowski P; Miceli R; Bylina E; Hohenberger P; Raut CP; Gronchi A
Ann Surg Oncol; 2012 Oct; 19(11):3361-7. PubMed ID: 22843188
[TBL] [Abstract][Full Text] [Related]
8. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
9. The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor.
Wang JP; Wang T; Huang MJ; Wang L; Kang L; Wu XJ
Am J Clin Oncol; 2011 Jun; 34(3):314-6. PubMed ID: 20622646
[TBL] [Abstract][Full Text] [Related]
10. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
11. Neoodjuvant imatinib mesylate for advanced primary and metastactic/recurrent gastro-intestinal stromal tumour (GIST).
Das D; Ganguly S; Deb AR; Aich RK
J Indian Med Assoc; 2013 Jan; 111(1):21-3. PubMed ID: 24000503
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
13. [Two cases of surgical resection of rectal gastrointestinal stromal tumor after neoadjuvant therapy with imatinib mesylate].
Nakashima S; Fujita Y; Matsuo H; Ariyoshi Y; Fukuda K; Fujiyama J; Masuyama M
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1932-4. PubMed ID: 23267934
[TBL] [Abstract][Full Text] [Related]
14. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
15. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors.
Seshadri RA; Rajendranath R
J Cancer Res Ther; 2009; 5(4):267-71. PubMed ID: 20160360
[TBL] [Abstract][Full Text] [Related]
17. A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era.
Reece-Smith AM; MacGoey P; Shah MA; Leeder P; Andrew DR; McCulloch T; Parsons SL
Eur J Surg Oncol; 2012 Jun; 38(6):484-9. PubMed ID: 22342866
[TBL] [Abstract][Full Text] [Related]
18. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
[TBL] [Abstract][Full Text] [Related]
19. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
20. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST.
An HJ; Ryu MH; Ryoo BY; Sohn BS; Kim KH; Oh ST; Yu CS; Yook JH; Kim BS; Kang YK
Ann Surg Oncol; 2013 Dec; 20(13):4212-8. PubMed ID: 24052319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
